Lawsuit Background: The Law Offices of Howard G. Smith announced that investors can join a securities fraud class action against Avantor, Inc. by December 29, 2025, due to undisclosed weaknesses in the company's competitive positioning, leading to significant investor losses.
Competitive Impact: The lawsuit alleges that between March 5, 2024, and October 28, 2025, Avantor failed to inform investors about the negative effects of increased competition, rendering the company's positive business outlook statements materially misleading and lacking a reasonable basis.
Legal Rights: Investors who suffered losses during the specified period can contact Howard G. Smith to understand their rights to participate in the lawsuit, indicating that the case could negatively impact Avantor's stock price and market confidence.
Participation in Lawsuit: Investors need not take immediate action to be part of the class action, suggesting that the case's potential implications may lead to broader legal and financial consequences.
AVTR
$11.28+Infinity%1D
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 13.86 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 13.86 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 11.170
Low
12.00
Averages
13.86
High
17.00
Current: 11.170
Low
12.00
Averages
13.86
High
17.00
BofA
Buy -> Neutral
downgrade
$14 -> $13
2025-12-15
New
Reason
BofA
Price Target
$14 -> $13
2025-12-15
New
downgrade
Buy -> Neutral
Reason
BofA downgraded Avantor to Neutral from Buy with a price target of $13, down from $14.
BofA
Neutral
to
Buy
upgrade
2025-12-15
New
Reason
BofA
Price Target
2025-12-15
New
upgrade
Neutral
to
Buy
Reason
BofA made several estimate and target changes across the firm's broader Biopharma Services names, upgrading Charles River (CRL), Mettler-Toledo (MTD) and Schrodinger (SDGR) all to Buy from Neutral and downgrading Zoetis (ZTS), Avantor (AVTR), Icon (ICLR) and Revvity (RVTY) to Neutral from Buy. 2026 will be the third year in a row where Life Science Tools headwinds are expected to fade and markets are expected to normalize, but the firm thinks "a healthy amount of caution is warranted," the analyst tells investors. BofA thinks the biggest upside risk for Tools/CRO markets will be a return to spending by Biopharma, and thus favors companies with relatively higher R&D exposure, adding that it thinks any misses or setbacks in the space "will be harshly punished."
Nephron Research
Jack Meeham
Hold
to
Sell
downgrade
$8
2025-12-11
New
Reason
Nephron Research
Jack Meeham
Price Target
$8
2025-12-11
New
downgrade
Hold
to
Sell
Reason
Nephron Research analyst Jack Meeham downgraded Avantor to Sell from Hold with an $8 price target.
Raymond James
Outperform -> Market Perform
downgrade
2025-11-04
Reason
Raymond James
Price Target
2025-11-04
downgrade
Outperform -> Market Perform
Reason
Raymond James downgraded Avantor to Market Perform from Outperform without a price target. The company reported another "frustrating quarter" with a miss on sales, the analyst tells investors in a research note. The firm cites Avantor's reduced guidance and execution risks for the downgrade. Raymond James sees a lack of visibility to continue recommending the shares.
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
